Potential Synergy Activity of the Novel Ceragenin, CSA-13, against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Bacteremia Patients

Table 1

Comparative in vitro activity of antimicrobial agents against 60 isolates of A. baumannii.

Antibiotics	mg/L						Percent inhibited at CLSI breakpoints^a
	MIC range	MIC50	MIC90	MBC range	MBC50	MBC90	Susceptible	M.S.^b	Resistant
CSA-13	1–16	2	8	1–32	2	16	—	—	—
Colistin	0.06–32	1	4	0.06–32	2	8	86	0	14
Tobramycin	0.3–160	1.25	80	0.3–160	2.5	160	45	0	55
Ciprofloxacin; meropenem	0.3–80; 16–128	80; 32	160; 64	0.6–160; 16–256	80; 64	160; 128	5; 0	0; 0	95; 100

aCLSI breakpoints for susceptible and resistant to colistin ≤2 mg/L and ≥4 mg/L; tobramycin ≤4 mg/L and ≥16 mg/L; ciprofloxacin ≤1 mg/L and ≥4 mg/L and meropenem ≤4 mg/L and ≥16 mg/L, respectively.
^bM.S.: moderately susceptible.